2008 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
12/30/08GTx Submits New Drug Application for Toremifene 80 mg for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy
MEMPHIS, Tenn.--(BUSINESS WIRE)--Dec. 30, 2008--GTx, Inc. (Nasdaq: GTXI) today announced the submission of a New Drug Application with the U.S. Food and Drug Administration (FDA) for toremifene 80 mg, an oral selective estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT). "ADT has helped improve survival for men with advanced prostate cancer. Unfortunately, ... 
Printer Friendly Version
11/11/08GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference
MEMPHIS, Tenn., Nov 11, 2008 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 18 at the Lazard Capital Markets 5th Annual Healthcare Conference in New York City. The GTx presentation will begin at 8:55 a.m. Eastern. A simultaneous webcast of the presentation will be accessible from the investor relations section of the GTx website at www.gtxinc.com. An archived replay of the presentatio... 
Printer Friendly Version
11/06/08GTx, Inc. Reports Third Quarter 2008 Financial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 6, 2008--GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2008. The net loss for the third quarter and nine months ended September 30, 2008 was $11.9 million and $37.9 million, respectively, compared with a net loss of $10.2 million and $27.6 million for the same periods in 2007. At September 30, 2008 GTx had cash, cash equivalents and short-term investments of $105.3 million. "We are pleased to report that our... 
Printer Friendly Version
11/04/08GTx Announces Corporate Presentation at Rodman & Renshaw Annual Healthcare Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 4, 2008--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 10 at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City. The GTx presentation will begin at 4:05 p.m. Eastern. A simultaneous webcast of the presentation will be accessible from the investor relations section of the GTx website at www.gtxinc.com. An archived replay of the presentation will be available on the company ... 
Printer Friendly Version
10/28/08GTx, Inc. Announces Third Quarter 2008 Financial Results Conference Call and Webcast
MEMPHIS, Tenn.--(BUSINESS WIRE)--Oct. 28, 2008--GTx, Inc. (Nasdaq: GTXI) today announced that it will host a conference call and webcast to discuss the Company's third quarter 2008 financial results on Thursday, November 6 at 9:00 a.m. Eastern. The call and webcast will follow the release of the third quarter 2008 financial results earlier that day. To listen to the conference call, please dial: -- 800-591-6944 from the United States and Canada or -- 617-614-4910 ... 
Printer Friendly Version
10/16/08GTx Announces Presentation of Toremifene 80 mg Data at Fourth Annual Chicago Supportive Oncology Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq: GTXI) announced that data from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of estrogen deficiency side effects of androgen deprivation therapy will be presented this evening in a moderated poster session at the Fourth Annual Chicago Supportive Oncology Conference. Poster number: PA-26 "Toremifene improved multiple side effects of ADT and slowed PSA progression in men in a Phase III clini... 
Printer Friendly Version
10/13/08GTx Announces Investigational Ostarine(TM) (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
MEMPHIS, Tenn--(BUSINESS WIRE)-- GTx, Inc. (NASDAQ: GTXI) today announced topline results of a Phase II clinical trial evaluating Ostarine(TM) (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia. In this analysis, the study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo and the secondary endpoint of muscle function (performance) after 1... 
Printer Friendly Version
09/18/08GTx to Present at the UBS Global Life Sciences Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Sept. 18, 2008--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on September 24 at the UBS 2008 Global Life Sciences Conference in New York City. The GTx presentation will begin at 9:00 a.m. Eastern. A simultaneous webcast of the presentation will be accessible from the investor relations section of the GTx website at www.gtxinc.com. An archived replay of the presentation will be available on the company website... 
Printer Friendly Version
09/16/08GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 mg Phase III ADT Clinical Trial
MONTREAL--(BUSINESS WIRE)--Sept. 16, 2008--GTx, Inc. (Nasdaq: GTXI) today presented a safety analysis demonstrating that fewer men treated with toremifene 80 mg had PSA progression over time compared to placebo in the Phase III clinical trial evaluating toremifene 80 mg for the treatment of multiple serious side effects of androgen deprivation therapy (ADT) for advanced prostate cancer. These data, as well as an additional analysis of bone turnover markers and fracture risk, were pres... 
Printer Friendly Version
09/10/08GTx to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research
MEMPHIS, Tenn.--(BUSINESS WIRE)--Sept. 10, 2008--GTx, Inc. (Nasdaq: GTXI) announced that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men with advanced prostate cancer will be presented September 16th in an oral session at the 2008 Annual Meeting of the American Society for Bone and Mineral Research being held in Montreal, Canada. The present... 
Printer Friendly Version
08/28/08GTx Announces Webcast of Corporate Presentation at the NewsMakers in the Biotech Industry Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Aug. 28, 2008--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview at the BioCentury NewsMakers in the Biotech Industry Conference on September 4 at the Millennium Broadway Hotel in New York City. The GTx presentation will begin at 9:30 a.m. Eastern Time. A simultaneous webcast of the presentation will be accessible from the GTx website at www.gtxinc.com. An archived replay of the presentation will be available on t... 
Printer Friendly Version
08/05/08GTx, Inc. Reports Second Quarter 2008 Financial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--Aug. 5, 2008--GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2008. The net loss for the second quarter and six months ended June 30, 2008 was $13.2 million and $26.0 million, respectively, compared with a net loss of $9.2 million and $17.3 million for the same periods in 2007. At June 30, 2008 GTx had cash, cash equivalents and short-term investments of $118.0 million. "In the second quarter, we continued to mak... 
Printer Friendly Version
07/28/08GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review
MEMPHIS, Tenn.--(BUSINESS WIRE)--July 28, 2008--GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). The DSMB meets every six months to review unblinded safety data from the toremifene Ph... 
Printer Friendly Version
07/22/08GTx, Inc. Announces Second Quarter 2008 Financial Results Conference Call and Webcast
MEMPHIS, Tenn.--(BUSINESS WIRE)--July 22, 2008--GTx, Inc. (Nasdaq: GTXI) today announced that it will host a conference call and webcast to discuss the Company's second quarter 2008 financial results on Tuesday, August 5 at 9:00 a.m. Eastern time. The call and webcast will follow the release of the second quarter 2008 financial results earlier that day. To listen to the conference call, please dial: -- 866-770-7120 from the United States and Canada or -- 617-213-8065 (Interna... 
Printer Friendly Version
06/03/08GTx Announces Webcast of Corporate Presentation at Goldman Sachs 29th Annual Global Healthcare Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--June 3, 2008--GTx, Inc. (Nasdaq: GTXI), announced today that management will present a company overview at the Goldman Sachs 29th Annual Global Healthcare Conference on June 10, 2008. The GTx presentation will begin at 1:20 p.m. Pacific time. A live webcast of the presentation may be accessed by visiting the GTx website at www.gtxinc.com. An archived replay of the webcast will be available for two weeks beginning approximately 3 hours after the live pr... 
Printer Friendly Version
05/23/08GTx Announces Phase III PIN Clinical Trial Will Continue As Planned
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 23, 2008--GTx, Inc. (Nasdaq: GTXI) today announced that an independent biometrics group recommended that the Phase III clinical trial evaluating toremifene 20 mg in men with high grade prostatic intraepithelial neoplasia, or PIN, who are at increased risk for prostate cancer should continue as planned following an interim efficacy analysis. In order to preserve the integrity of the clinical trial and allow the study to continue without introducing ... 
Printer Friendly Version
05/12/08GTx, Inc. Reports First Quarter 2008 Financial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 12, 2008--GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter of 2008. The net loss for the quarter ended March 31, 2008 was $12.7 million, compared with a net loss of $8.1 million for the same period in 2007. At March 31, 2008, GTx had cash, cash equivalents and short-term investments of $134.7 million. "Our first quarter announcement that the toremifene 80 mg Phase III ADT clinical trial met its primary endpoint wa... 
Printer Friendly Version
05/06/08GTx Appoints Kenneth S. Robinson, MD to the Board of Directors
MEMPHIS, Tenn., May 06, 2008 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) today announced that Kenneth S. Robinson, MD, MDiv, has been appointed to its Board of Directors. Dr. Robinson will serve as a member of the Board's Nominating and Corporate Governance Committees. "Dr. Robinson brings to GTx leadership in public health policy, and we welcome him to the board of directors," said Dr. Mitchell S. Steiner, CEO of GTx. Dr. Robinson holds a B.A., cum laude, from Harvard University, a M.... 
Printer Friendly Version
04/28/08GTx, Inc. Announces First Quarter 2008 Financial Results Conference Call and Webcast
MEMPHIS, Tenn.--(BUSINESS WIRE)--April 28, 2008--GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to discuss the Company's first quarter 2008 financial results on Monday, May 12 at 9:00 a.m. Eastern. The call and webcast will follow the release of the first quarter 2008 financial results earlier that day. To listen to the conference call, please dial: -- 866-831-6270 from the United States and Canada or -- 617-213-8858 (International) ... 
Printer Friendly Version
04/15/08First Fracture Prevention Study in Men Receiving ADT for Prostate Cancer Presented at AACR Annual Meeting
Phase III Clinical Trial Results Demonstrate Toremifene Citrate 80 mg Compared to Placebo Reduced Fractures and Treated Multiple Other Estrogen Related Side Effects of ADT SAN DIEGO--(BUSINESS WIRE)--April 15, 2008--GTx, Inc. (NASDAQ: GTXI) announced that results of the Phase III ADT clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men who have advanced prostate cancer were... 
Printer Friendly Version
04/08/08GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg Phase III ADT Clinical Trial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--April 8, 2008--GTx, Inc. (NASDAQ: GTXI) today announced that the results of the Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) for advanced prostate cancer will be presented during a late breaking oral presentation at the 2008 Annual Meeting of the American Association for Cancer Research being held in San Diego April 12 - 16. Matthew R. Smith, MD, PhD, D... 
Printer Friendly Version
03/12/08GTx Announces Webcast of Corporate Presentation at the Lehman Brothers Global Healthcare Conference
MEMPHIS, Tenn., Mar 12, 2008 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview at the Lehman Brothers Global Healthcare Conference on March 19 in Miami. The GTx presentation, which will highlight the company's clinical development programs and the recently announced results of the ACAPODENE(R) 80 mg Phase III ADT clinical trial, will begin at 2:00 p.m. Eastern Time. A simultaneous webcast of the presentation will be accessible from ... 
Printer Friendly Version
03/10/08GTx Announces Webcast of Corporate Presentation at the 28th Annual Cowen and Company Health Care Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--March 10, 2008--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview at the 28th Annual Cowen and Company Health Care Conference on March 17 in Boston. The GTx presentation, which will highlight the company's clinical development programs and the recently announced results of the ACAPODENE(R) 80 mg Phase III ADT clinical trial, will begin at 4:45 p.m. Eastern Time. A simultaneous webcast of the presentation will be a... 
Printer Friendly Version
03/03/08GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
The Most Common Symptomatic Side Effect Experienced by Men on ADT is Hot Flashes MEMPHIS, Tenn.--(BUSINESS WIRE)--March 3, 2008--GTx, Inc. (NASDAQ: GTXI) today announced that toremifene citrate 80 mg reduced hot flashes in men with prostate cancer on androgen deprivation therapy (ADT), a key secondary endpoint of the Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of ADT for advanced prostate cancer. In an analysis o... 
Printer Friendly Version
02/25/08GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Results Show a 50 Percent Reduction in Incidence of Androgen Deprivation Induced Osteoporosis Related Vertebral Fractures MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 25, 2008--GTx, Inc. (NASDAQ:GTXI) today announced Phase III clinical data for toremifene citrate 80 mg, the Company's investigational therapy for the treatment of multiple side effects of androgen deprivation therapy (ADT) for advanced prostate cancer. Results show that toremifene citrate 80 mg reduced vertebral fr... 
Printer Friendly Version
02/19/08GTx Reports Fourth Quarter and Year End 2007 Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 19, 2008--GTx, Inc. (Nasdaq: GTXI), today reported financial results for the fourth quarter and year ended December 31, 2007. The net loss for the three months and year ended December 31, 2007 was $12.8 million and $40.4 million, respectively, compared with a net loss of $4.7 million and $35.5 million for the same periods in 2006. At December 31, 2007, GTx had cash and cash equivalents and short-term investments of $110 million. Subsequent to the ... 
Printer Friendly Version
02/05/08GTx, Inc. Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and Webcast
MEMPHIS, Tenn., Feb 05, 2008 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) today announced that it will host a conference call and webcast to discuss the Company's fourth quarter and year end 2007 financial results on Tuesday, February 19 at 9:00 a.m. Eastern. The call and webcast will follow the release of the fourth quarter and year end 2007 financial results earlier that day. To listen to the conference call, please dial: -- 800-573-4754 from the United States and Canada or -- 617-22... 
Printer Friendly Version
01/03/08GTx Announces Webcast of Corporate Presentation at the 26th Annual JP Morgan Healthcare Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Jan. 3, 2008--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview at the 26th Annual JP Morgan Healthcare Conference on January 10 in San Francisco. The GTx presentation, which will highlight the company's clinical development programs and pipeline of preclinical product candidates, will begin at 8:30 a.m. Pacific Time. A simultaneous webcast of the presentation will be accessible from the GTx website at www.gtxinc.... 
Printer Friendly Version